Bioventus has expanded its European reach by launching its company and products in Italy. The company, which opened its international headquarters in the Netherlands in December 2012, delivers products that aim to aid the fixation of fractures quickly and safely.
With corporate headquarters in the US, Bioventus was formed in May 2012 as a strategic partnership between the company's owners, Smith & Nephew (S&N) and an Essex Woodlands-led investor syndicate group. With the Italian launch, S&N's biologics and clinical therapies business in Italy, including employees and products, has transitioned over to Bioventus. The products available in Italy will switch from their current S&N labelling to Bioventus. The products themselves will not change. They include:
â¢ Exogen ultrasound bone healing system, a product indicated in Europe to accelerate the healing of recent fractures and to heal fractured bones with either delayed unions or non-unions. Exogen has been shown to heal 86 per cent of non-union fractures and accelerate the healing of fresh fractures up to 38 per cent faster than competing products. Exogen is developed and marketed by Bioventus worldwide.
â¢ Durolane, a single-injection, 3mL, joint-fluid treatment to relieve mild-to-moderate osteoarthritis (OA) pain of all sizes of synovial joints. A 1mL version of the product, Durolane SJ, is also available and indicated for treatment of OA pain in small joints. Durolane is developed/manufactured by Q-Med and marketed by Bioventus in many countries outside the US.